Mode
Text Size
Log in / Sign up

NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models.

NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcin…
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider NR2F2 as a theoretical target for CAFs-TGF-β-EMT axis in lung adenocarcinoma, pending clinical validation.

This study utilized an observational cohort design supported by in vitro validation to investigate cancer-associated fibroblasts (CAFs) in patients with lung adenocarcinoma. Data were sourced from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and an independent validation cohort (GSE72094). The intervention involved computational analysis of CAF subgroups, specifically the CAF-2 subgroup, and NR2F2 expression levels. In vitro experiments included siRNA knockdown and plasmid overexpression of NR2F2 within a coculture system.

The primary outcome was the identification of CAF subgroups and the construction of a prognostic gene signature. Using the LASSO-Cox method, researchers constructed and verified a consistent prognostic signature of 16 genes. Patients in the high-risk group derived from this signature demonstrated worse prognosis compared to the low-risk group. Additionally, the risk score showed a positive association with an immunosuppressive tumor microenvironment and high expression of PD-L1.

In vitro manipulation of NR2F2 revealed that overexpression in CAFs enhanced tumor cell proliferation and invasion. Conversely, knockdown of NR2F2 attenuated these malignant phenotypes. The study also noted that NR2F2 expression is associated with promoting matrix remodeling and metabolic reprogramming. No adverse events or safety data were reported, as the study focused on computational analysis and laboratory experiments rather than clinical administration.

Key limitations include the reliance on public database analysis and in vitro models, with no clinical trial data available. Causality cannot be established for human patients based on these observational associations. The practice relevance lies in providing a theoretical foundation for exploring new options targeting the CAFs-TGF-β-EMT axis, suggesting NR2F2 as a potential target for future therapeutic development.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe high heterogeneity of lung adenocarcinoma (LUAD) is largely due to its complex tumor immune microenvironment (TIME). Cancer-associated fibroblasts (CAFs) are a core matrix component of TIME. However, their functional heterogeneity and the specific molecular mechanisms driving tumor progression have not been fully elucidated. In addition, the role of nuclear receptor NR2F2 in tumor development is still controversial.MethodThis study integrated scRNA-seq data from the GEO database with RNA-seq data from TCGA and GEO and then performed multiple levels of validation through in vitro experiments. We adopted a systematic computational biology strategy and analyzed the cellular composition, interaction networks and functional states of cancer-associated fibroblasts (CAFs) in lung adenocarcinoma using Seurat, CellChat, and AUCell. According to the marker genes of key CAF subgroup, prognostic risk models were constructed through LASSO-Cox regression and validated in an independent cohort (GSE72094). Afterwards, we carried out in vitro experiments and validated the biological role of NR2F2 through a coculture system. Functional validation was conducted through siRNA knockdown, plasmid overexpression, CCK-8 assay, EdU labeling, and Transwell experiments.ResultWe noticed the CAF - 2 subgroup, characterized by the highest level of TGF - β signaling activation, sends various signals to different cell types. We constructed and verified a consistent prognostic signature made of 16 genes using the LASSO-Cox method. This model can effectively assess the risk of LUAD patients. The prognosis in high-risk group is worse. And we also do some analysis to find out that risk score is highly associated with immunosuppressive TME and high expressions of PD - L1. We have found in our further study that the expression of NR2F2 in CAF is associated with the promoting of matrix remodeling and metabolic reprogramming. From the coculture system and in vitro functional experiments, overexpression of NR2F2 in CAFs enhanced tumor cell proliferation and invasion, whereas knockdown of NR2F2 attenuated these malignant phenotypes.ConclusionUsing single-cell RNA sequencing data, we identified a CAF subgroup with the most active TGF-β signaling. Based on the marker genes of the subgroup, we constructed and validated an effective prognostic model, then we further screened and confirmed NR2F2 as a major pro-tumorigenic regulator from this feature gene set through single cell and transcriptome data as well as in vitro experiments. NR2F2 promotes malignant remodeling of TIME by synergistically enhancing TGF-β signaling and EMT processes. Our study provides not only a solid theoretical foundation but also a therapeutic target to explore new therapeutic options targeting the CAFs-TGF-β-EMT axis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.